GENE ONLINE|News &
Opinion
Blog

Hong Kong
BIOHK2023: A Place Where Biotechnology Meets Financial Economics
2023-09-21
2023 International Healthcare Week: Showcasing Emerging Competencies of Hong Kong’s Biomedical Industry
2023-06-05
CK Life Sciences and CK Hutchison Invest in Taiwanese Liquid Biopsy Candidate
2022-07-26
Quion Licenses Two Rare Skin Disease Candidates to Hong Kong WinHealth
2022-06-16
UMP Healthcare Expands Free Telemedicine and Drug Delivery to COVID-19 Patients
2022-03-31
Bavarian Nordic Establishes Asia Link for Its RSV Vaccines
2022-03-24
Fifth Wave of COVID-19 Devastates Hong Kong – How Next-Generation Sequencing Can Help with Latest Outbreak
2022-03-08Partner
How Our Microbiomes Are Connected to Irritable Bowel Syndromes, Cancer and Autism: Highlights from the 6th Asia Microbiome Conference
2022-02-14
Scientists Work On an Oral Vaccine Booster for COVID-19
2022-01-07
GeneOnline’s Top 10 Hong Kong Biotech IPOs of 2021
2022-01-07
RNAi Player Sirnaomics Squeezes in $50 Million IPO in Hong Kong
2022-01-03
CStone Wins Hong Kong Approval for Gastrointestinal Tumor Drug
2021-12-29
Experts Discuss What’s Next for Healthcare Innovation and Investment at ASGH
2021-12-02
Could this Biotech be the First Billion-Dollar Hong Kong Startup to Go Public?
2021-07-18
Lifebit Provides BioMedical ICT Solution for Hong Kong’s Large-Scale Genome Sequencing Project
2021-05-27
1 2
LATEST
Sanofi and Regeneron’s Dupixent Approved as First-in-World Treatment For Uncontrolled COPD
2024-07-04
Advancements in Alzheimer’s Disease Drug Innovation and Funding Programs in 2024
2024-07-04
FDA Greenlights Eli Lilly’s Groundbreaking Alzheimer’s Drug Kisunla for Early Symptomatic Treatment
2024-07-04
BIO Asia–Taiwan 2024 Set to Showcase Global Biotech Industry Talent on July 24th
2024-07-03
Novo Nordisk’s CLARION-CKD Trial Shut Down After Unsuccessful Results Causing Impairment Loss
2024-07-03
Tanvex BioPharma Secures Asia’s First FDA Approval for Filgrastim Biosimilar, Seizing a $403 Million Market
2024-07-03
Ginkgo Job Cuts Expected to Affect at Least 35% of Workforce, Eliminating Over 400 Jobs
2024-07-02
EVENT
Scroll to Top